Lixisenatide: First Global Approval

被引：26

作者：

Elkinson, Shelley ^{[1
]}

Keating, Gillian M. ^{[2
]}

机构：

[1] Adis R&D Insight, Auckland 0754, New Zealand

[2] Adis, Auckland, New Zealand

来源：

DRUGS | 2013年 / 73卷 / 04期

关键词：

GLP-1 RECEPTOR AGONIST; PLACEBO-CONTROLLED TRIAL; ONCE-DAILY LIXISENATIDE; DOUBLE-BLIND; BASAL INSULIN; TYPE-2; EFFICACY; SAFETY; METFORMIN; SULFONYLUREA;

D O I：

10.1007/s40265-013-0033-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia (R)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin secretion in a glucose-dependent manner, as well as suppressing glucagon production and slowing gastric emptying. A once-daily subcutaneous formulation of lixisenatide has been approved in the EU, Iceland, Liechtenstein, Norway and Mexico for the treatment of type 2 diabetes, and is under regulatory review in the USA, Switzerland, Brazil, Canada, Ukraine, South Africa, Japan and Australia. This article summarizes the milestones in the development of lixisenatide, leading to this first approval for use in adults with type 2 diabetes.

引用

页码：383 / 391

页数：9

共 38 条

[1]

Ahren B, 2011, 21 WORLD DIAB C DUB

[2]

Aventis Zealand Pharma AS, 2003, AV ZEAL PHARM SIGN L

[3]

Becker RH, 2012, DIABETOLOGIA, V55, pS335

[4]

Bolli G, 2011, DIABETOLOGIA, V54, pS316

[5] The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist [J].

Christensen, Mikkel ;

Knop, Filip K. ;

Vilsboll, Tina .

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (04) :513-525

[6]

Christensen M, 2009, IDRUGS, V12, P503

[7]

Dahmen R, 2011, 10 C EUR ASS CLIN PH

[8]

Distiller L, 2008, DIABETES, V57, pA154

[9]

European Medicines Agency, 2013, LYX LIX EU SUMM PROD

[10] Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) [J].

Fonseca, Vivian A. ;

Alvarado-Ruiz, Ricardo ;

Raccah, Denis ;

Boka, Gabor ;

Miossec, Patrick ;

Gerich, John E. .

DIABETES CARE, 2012, 35 (06) :1225-1231

← 1 2 3 4 →